drugset / Trial / NCT05134519
RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm exploratory study to explore the effect of RC48 in HER2-positive neoadjuvant therapy and evaluate the non-inferiority of RC48 by comparing the latest reported data of T-DM1 in neoadjuvant therapy.
Timeline
- Start
- 2021-11-26
- Primary completion
- 2024-09-30
- Completion
- 2025-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |